Emera Inc.(EMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EMA Emera Inc.

Trading 03-18 11:52:28 EDT

53.12

-0.32

-0.60%

High53.75	Low53.11	Vol55.37K
Open53.75	D1 Closing53.44	Amplitude1.20%
Mkt Cap16.03B	Tradable Cap15.88B	Total Shares301.75M
T/O2.95M	T/O Rate0.02%	Tradable Shares298.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":53.12,"timestamp":1773849126172,"preClose":53.44,"halted":0,"volume":55369,"delay":0,"changeRate":-0.005988023952095814,"floatShares":298863171,"shares":301745499,"eps":2.465138,"marketStatus":"Trading","change":-0.32,"latestTime":"03-18 11:52:28 EDT","open":53.75,"high":53.75,"low":53.11,"amount":2945238.399897,"amplitude":0.011976,"askPrice":53.13,"askSize":174,"bidPrice":53.1,"bidSize":40,"shortable":3,"etf":0,"ttmEps":2.465138,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":53.44,"dividendRate":0.040103,"postHourTrading":{"tag":"盘后","latestPrice":53.44,"preClose":53.44,"latestTime":"16:41 EDT","volume":105355,"amount":5636373.867856,"timestamp":1773780075421,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.489027,"impliedVol":0.0794,"impliedVolPercentile":0.2},"requestUrl":"/m/hq/s/EMA","defaultTab":"news","newsList":[{"id":"2620292231","title":"Press Release: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292231","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292231?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:00","pubTimestamp":1773828000,"startTime":"0","endTime":"0","summary":"Business development: Added 22 assets to portfolio, including five programs in Phase 2 or Phase 3 development. Stock buyback program: Repurchased and retired 648,048 shares for an aggregate of $16.0 million. Company acquisitions: Completed seven acquisitions, accumulating $11.7 million of non-dilutive capital , economic interests of approximately 25% in up to $1.1 billion of milestones and low to mid-single digit royalties from eight partnered programs. Key 2026 pipeline events: -- Phase 2b data from volixibat in PSC in Q2 and Phase 3 data from ersodetug in tumor HI in 2H -- Potential for EMA decisions on OJEMDA and MIPLYFFA marketing authorization applications -- Regulatory updates related to ersodetug in congenital HI and seralutinib in PAH. EMERYVILLE, Calif., March 18, 2026  -- XOMA Royalty Corporation , the biotech royalty aggregator, reported its 2025 fourth quarter and full year financial results and highlighted recent actions that have the potential to deliver additional shareh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","PSC","BK4604","PBC","EMA","R","BK4232","BK4139","BK4585","BK4555","BK4081","XOMA","03160","CHMP","TM","BK4087","BK4588","BK4022"],"gpt_icon":0},{"id":"2620044253","title":"Dogecoin Removed Zero From Its Price, But There Are 3 Reasons Why It Is Temporary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620044253","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620044253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:56","pubTimestamp":1773795360,"startTime":"0","endTime":"0","summary":"Recently, Dogecoin surged back above the $0.10 mark, essentially removing a zero from its price and momentarily boosting retail traders' moods. The meme coin community is often excited by such moves because psychologically round levels tend to draw attention.However, the move above $0.10 might not be as significant as it first appears. This development may turn out to be transient rather than the start of a long-term rally, for a number of structural and technical reasons.Is it psychologically appealing?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/dogecoin-removed-zero-from-its-price-but-there-are-3-reasons-why-it-is-temporary","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/dogecoin-removed-zero-from-its-price-but-there-are-3-reasons-why-it-is-temporary","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["EMA","EMA.AU","DOGE.USD.HKCC","BK7129","BK4081"],"gpt_icon":0},{"id":"2620253099","title":"Crypto Market Review: Is Bitcoin Ready for $100,000? Shiba Inu (SHIB) Bull Market Denied Abruptly, Ethereum's (ETH) Next Key Resistances Are Clear Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253099","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253099?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:01","pubTimestamp":1773763260,"startTime":"0","endTime":"0","summary":"SHIB would have needed to break above the 50 EMA and maintain that level as support in order for a real trend reversal to take place. Rather, the ina","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/crypto-market-review-is-bitcoin-ready-for-100000-shiba-inu-shib-bull-market-denied-abruptly","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/crypto-market-review-is-bitcoin-ready-for-100000-shiba-inu-shib-bull-market-denied-abruptly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["EMA","ETHI","SETH","BTF","09179","FETH","CETH","YETH","ETHU","BK4081","09042","09439","ETCO","METHmain","ETHD","09008","QETH","EMA.AU","09009","BK4594","BK4588","ETH","ETQ","EETH","BK7129","ETH.USD.HKCC","ETU","ETH.USD.CC","EZET","ETHW","ETHE","09046","ETHA","ETHV","ETHT","BK4585","BK4601"],"gpt_icon":1},{"id":"2620429871","title":"X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429871","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429871?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":"- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257025/0/en/X4-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4156","EC","BK4087","MSL","EMA","BK4081","BK4201"],"gpt_icon":0},{"id":"2620470986","title":"Shiba Inu One Step Away From Crossing 81 Trillion Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2620470986","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620470986?lang=en_us&edition=fundamental","pubTime":"2026-03-17 12:07","pubTimestamp":1773720420,"startTime":"0","endTime":"0","summary":"With exchange reserves getting closer to the 81 trillion token threshold Shiba Inu is currently on the verge of a significant on-chain milestone. The asset price movement also shows that the market is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/shiba-inu-one-step-away-from-crossing-81-trillion-threshold","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/shiba-inu-one-step-away-from-crossing-81-trillion-threshold","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK7129","BK4081","EMA","EMA.AU"],"gpt_icon":0},{"id":"2620749500","title":"XRP Breaks Biggest Technical Resistance of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620749500","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620749500?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:55","pubTimestamp":1773626100,"startTime":"0","endTime":"0","summary":"After months of declining pressure, XRP is starting to show signs of life, and it is currently confronting one of the most significant technical obstacles of 2026. XRP has advanced toward a crucial resistance area that traders have been closely monitoring since the beginning of the year, after creating a consistent sequence of higher lows over the previous few weeks.Multiple resistances brokenXRP has broken through a descending resistance structure that had previously limited several attempts at recovery, and it is currently trading at about $1.48.The asset's peak above $3 earlier in the cycle was followed by a sharp decline. This move represents the first significant change in market structure since then. Although the breakout itself is noteworthy, XRP's true test is still to come.XRP/USDT Chart by TradingViewThe asset is currently getting closer to the 50-day exponential moving average , which remains a significant resistance level and is located just above the current price. The 50 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/xrp-breaks-biggest-technical-resistance-of-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/xrp-breaks-biggest-technical-resistance-of-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK7129","BK4081","EMA.AU","EMA","XRP"],"gpt_icon":0},{"id":"2619837234","title":"XRP Ledger Crosses 2.5 Million Threshold in 24 Hours as Market Performance Stales","url":"https://stock-news.laohu8.com/highlight/detail?id=2619837234","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619837234?lang=en_us&edition=fundamental","pubTime":"2026-03-15 12:48","pubTimestamp":1773550080,"startTime":"0","endTime":"0","summary":"The current configuration has a slightly different appearance. Directly below resistance, the market has entered a tight consolidation phase rather than an aggressive rejection. While both buyers and sellers wait for a catalyst, such compression frequently occurs before a final decision.The recent spike in XRP Ledger activity, which suggests that the underlying network is seeing increased usage, is another element bolstering the bullish argument. When the number of transactions increases while the price remains stable, it may indicate that the underlying fundamentals are getting stronger.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/xrp-ledger-crosses-25-million-threshold-in-24-hours-as-market-performance-stales","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/xrp-ledger-crosses-25-million-threshold-in-24-hours-as-market-performance-stales","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["EMA.AU","BK4081","BK7129","XRP","EMA"],"gpt_icon":0},{"id":"2619162495","title":"CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162495","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619162495?lang=en_us&edition=fundamental","pubTime":"2026-03-13 16:25","pubTimestamp":1773390300,"startTime":"0","endTime":"0","summary":"SHENZHEN, CHINA, March  13, 2026 (GLOBE NEWSWIRE) -- On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limite","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/13/3255280/0/en/CMS-867-HK-8A8-SG-Ruxolitinib-Phosphate-Cream-Lumirix-Achieves-Initial-Prescriptions-in-Multiple-Regions-in-China-for-Patients-with-Vitiligo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1883839398.USD","LU1003077747.HKD","TCS","LU0661504455.SGD","BK4200","AD","LU1880398554.USD","LU0949170772.SGD","LU0545039389.USD","LU1894683264.USD","LU2500361329.USD","LU0738911758.USD","BK4588","BK4585","LU1880398471.USD","BK4208","BK4132","LU1894683348.USD","EMA","BK4081","LU2346227817.USD","CMS","LU2637428348.USD","RF","LU0553294199.USD","BK4211"],"gpt_icon":0},{"id":"2618907060","title":"Press Release: Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow","url":"https://stock-news.laohu8.com/highlight/detail?id=2618907060","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618907060?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:00","pubTimestamp":1773295200,"startTime":"0","endTime":"0","summary":"-- Full year 2025 total revenues increased by 27% to US$376.1 million,driven by continued growth of RUCONEST and rising demand for Joenja. fourth quarter revenue increased by 9% to US$86.7 million. -- Joenja revenue increased by 29% to US$58.2 million and fourth quarter. growth), driven by significant and accelerating growth for Joenja and. \"2025 was a defining year for Pharming and reflects the focus and discipline our teams have brought to executing our strategy. We outperformed revenue guidance and delivered strong financial performance, with total revenues up 27%, driven by continued RUCONEST growth and rising demand for Joenja .Building on this momentum, we plan to further enhance capital allocation to drive growth. We expect 2026 total revenues in the range of US$405 million to US$425 million, representing 8% to 13% growth, driven by both Joenja and RUCONEST.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4530","EMA","CHMP","BK4022","PHAR","EEA","IE00BFMHRM44.USD","PK","LU0029874061.USD","BK4087","MAA","CRL","R","LU1815336091.USD","BK4585","BK4081","BK4181","LU0757428866.USD","LU0390134368.USD","BK4218","BK4588","BK4121","BK4232","BK4139","BK4215","LU0128526141.USD"],"gpt_icon":0},{"id":"2618956571","title":"Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956571","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618956571?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:25","pubTimestamp":1773149100,"startTime":"0","endTime":"0","summary":"Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, inc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252978/0/en/Capricor-Therapeutics-Announces-Establishment-of-New-PDUFA-Date-for-Deramiocel-BLA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CAPR","EMA","BK4139","LABU","BK4081","BK4585","ATMP"],"gpt_icon":0},{"id":"2618687955","title":"Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2618687955","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618687955?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:00","pubTimestamp":1773147600,"startTime":"0","endTime":"0","summary":"CHICAGO, Ill., March  10, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252935/0/en/Cosmos-Health-Enters-into-LOI-to-Acquire-11-500-000-Pharmacy-Distribution-Network-Remains-on-Track-to-Deliver-2027-Revenue-Guidance-of-155-800-000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4175","BK4081","COSM"],"gpt_icon":0},{"id":"2618632930","title":"LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia","url":"https://stock-news.laohu8.com/highlight/detail?id=2618632930","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618632930?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ’s strategy to expand global access toVIZZ Submission of MAA in Europe results in the fifth ex-U.S. regulat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252745/0/en/LENZ-Therapeutics-Announces-Submission-of-Marketing-Authorization-Application-to-European-Medicines-Agency-for-VIZZ-for-the-Treatment-of-Presbyopia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4215","BK4081","BK4588","BK4139","MDCO","BK4539","MAA","BK4007","EMA","LENZ"],"gpt_icon":0},{"id":"2618528642","title":"Press Release: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy(R) (epinephrine nasal spray) Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2618528642","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618528642?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050400,"startTime":"0","endTime":"0","summary":"neffy delivers $72.2 million of U.S. net product revenue in first full year. Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026. Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even. \"2025 was an important year for ARS Pharma as we established neffy as a differentiated, scalable epinephrine treatment of choice. We have built a strong base business with initial prescriptions expected to begin renewing in 2026 as product reaches expiration. This shift towards renewals, combined with continued growth in new neffy patients, positions us to accelerate market share expansion,\" said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma.and $0.9 million in supply revenue from partners. The cash value of. and $0.1 million was recorded to the financing liability on the company's. collaboration revenue, and $2.4 million from supply agreements. The cash","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4139","BK4500","EMA","BK4585","BK4081","BK4022","BK4588","SPRY","BK4232","CHMP","BK4008","R","ALK"],"gpt_icon":0},{"id":"2617805916","title":"Press Release: Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617805916","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617805916?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:45","pubTimestamp":1772801100,"startTime":"0","endTime":"0","summary":"- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 -. - Dosing in Phase 2 trial of atebimetinib + Libtayo in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 -. - Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 -. NEW YORK, March 06, 2026  -- Immuneering Corporation , a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4232","R","BK4022","BK4563","IMRX","BK4097","EMA","OS","BK4539","BK4139"],"gpt_icon":0},{"id":"2617636015","title":"What's Going On With Anavex Life Sciences Stock On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636015","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617636015?lang=en_us&edition=fundamental","pubTime":"2026-03-05 02:32","pubTimestamp":1772649120,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzheimer's program updates and analyst targets.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/04/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/04/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51045535/whats-going-on-with-anavex-life-sciences-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51045535/whats-going-on-with-anavex-life-sciences-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["AVXL","CHMP","EMA","BK4139","BK4087","BK4081"],"gpt_icon":0},{"id":"2616530176","title":"NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616530176","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616530176?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:30","pubTimestamp":1772627400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, March  04, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249258/0/en/NervGen-Pharma-Appoints-Shamim-Ruff-as-Chief-Regulatory-Affairs-Officer-and-Christine-McSherry-as-SVP-Patient-Advocacy-and-Clinical-Affairs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4192","BK4007","LU0266013472.USD","EMA","LU1989771016.USD","BK4081","LU0077335932.USD","LU1892829315.USD","LU1291159041.SGD","NGEN","BK4548","SCI"],"gpt_icon":0},{"id":"2616537654","title":"Press Release: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616537654","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616537654?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:15","pubTimestamp":1772626500,"startTime":"0","endTime":"0","summary":"On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenstrm Macroglobulinemia. Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026. \"2025 was a productive year for Cellectar, marked by disciplined execution across our pipeline and meaningful clinical, regulatory, and operational achievements,\" said James Caruso, president and CEO of Cellectar. \"We advanced iopofosine I-131 toward its planned mid-2026 Conditional Marketing Authorization  submission in Europe, supported by a strong clinical dataset and productive dialogue with both the European and U.S. regulatory agencies. In parallel, we continued to shape the future of our radiotherapeutic platform with the initiation of our Phase 1b CLR 125 study in triple negative breast cancer and strengthened our supply chain and intellectual property ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211814178.USD","LU1430594728.SGD","LU2362540622.SGD","CLRB","LU2238339852.HKD","LU2111349929.HKD","LU2089283258.USD","BK4534","LU0175139822.USD","LU0289961442.SGD","LU2023250843.SGD","CMA","LU1989772840.SGD","03160","LU0289960550.SGD","BK4139","LU2023250504.SGD","LU0124676726.USD","LU2298064838.USD","PDC","BK4099","LU2308191902.HKD","LU2362541513.USD","LU1585245621.USD","LU1989772923.USD","LU2028103732.USD","LU2023251221.USD","BK4566","LU0511384066.AUD","LU1974910355.USD","LU2229751404.USD","LU2125910179.SGD","WM","EMA","LU2413666699.HKD","LU2125910336.SGD","CNS","LU0158827948.USD","LU0689626769.HKD","LU0057025933.USD","LU2271345857.HKD","TM","LU2106854487.HKD","LU1721428933.USD","BK4135","BK4533","LU1712237335.SGD","LU2355687059.USD","LU0069063385.USD","LU1623119135.USD"],"gpt_icon":0},{"id":"2616753751","title":"EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2616753751","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616753751?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:00","pubTimestamp":1772625600,"startTime":"0","endTime":"0","summary":"– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Ca","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249208/0/en/EyePoint-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Corporate-Developments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4554","LU1064131342.USD","LU1861559042.SGD","EYPT","EMA","LU1303367103.USD","IE00BHPRN162.USD","AMYY","LU1803068979.SGD","CMC","BK4585","LU0889565833.HKD","LU0823434740.USD","AMDU","LU1880398554.USD","LU2237443549.SGD","GFS","DAMD","LU0719512351.SGD","LU0823434583.USD","IE00BMPRXR70.SGD","AMDY","BK4588","AMDW","LU0390134368.USD","IE00BKVL7J92.USD","AMDL","AMDG","LU0320765992.SGD","AMUU","LU2458330169.SGD","BK4543","LU2237443978.SGD","LU2264538146.SGD","LU2355687059.USD","DSMC","LU2098885051.SGD","LU0081259029.USD","LU0889565916.HKD","LU1988902786.USD","LU0882574139.USD","LU2360106780.USD","IE00BZ1G4Q59.USD","LU0823421416.USD","LU0170899867.USD","LU0979878070.USD","AMDD","BK4534","LU1951198990.SGD"],"gpt_icon":1},{"id":"2616379179","title":"Press Release: CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2616379179","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616379179?lang=en_us&edition=fundamental","pubTime":"2026-03-04 04:26","pubTimestamp":1772569560,"startTime":"0","endTime":"0","summary":"--  Apitegromab Biologics License Application  resubmission and U.S.launch, following FDA approval, are anticipated in 2026 for the treatment. of children and adults with spinal muscular atrophy . --  FDA completed constructive meeting with Catalent Indiana, LLC (part of. Novo Nordisk), with discussion of remediation progress and no additional. with EMA decision anticipated in mid-2026; European launch expected in H2. --  Secured new debt facility, providing up to $550 million in non-dilutive. --  Cash, cash equivalents, and marketable securities of $367.6 million as. --  Management to host conference call today at 8:00 a.m. ET. SCHOLAR ROCK REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS. capital to support commercialization of apitegromab and strategic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","IE00BN8TJ469.HKD","BK4588","SRRK","SMA","IE00BLSP4452.SGD","OWL","BK4139","BK4217","IE00BBT3K403.USD","MAA","IE00BLSP4239.USD","BK4585","EMA","BK4215","BK4135"],"gpt_icon":0},{"id":"2616325798","title":"REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616325798","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616325798?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:00","pubTimestamp":1772546400,"startTime":"0","endTime":"0","summary":"Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services. As part of this platform, the StemRNA Clinical iPSC Seed Clone – LLF-34-F3, derived from US sourced donor material, is supported by an active FDA Drug Master File . This clone has been expanded into a GMP MCB using FDA-compliant closed system processes. This off-the-shelf GMP iPSC MCB is now available for commercial use, providing ready-to-use clinically validated starting material. For sponsors requiring European alignment, REPROCELL also offers MCB/WCB manufacturing through its partner, Histocell. This service operates with a GMP certificate and authorization from the Spanish Agency for Medicines and Medical Devices  under European Medicines Agency  oversight.US-generated StemRNA Clinical Seed Clones supported by an active FDA DMF","market":"us","thumbnail":"https://mma.prnewswire.com/media/2800592/REPROCELL_USA_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2800592/REPROCELL_USA_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/reprocell-launches-gmp-master-cell-bank-manufacturing-for-clinical-ipscs-302700233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK7129","WGS","MCB","BK4211","DMF","BK4081","EMA.AU","BK4196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0383},{"period":"3month","weight":0.1009},{"period":"6month","weight":0.166},{"period":"1year","weight":0.1802},{"period":"ytd","weight":0.0853}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Emera Incorporated, through its subsidiaries, engages in the generation, transmission, and distribution of electricity to various customers. The company operates through Florida Electric Utility, Canadian Electric Utilities, Other Electric Utilities, Gas Utilities and Infrastructure, and Other segments. It generates electricity through natural gas, solar, hydroelectricity, coal, and biomass power plants. The company is also involved in the purchase, transmission, distribution, and sale of natural gas; and the provision of energy marketing, trading, and other energy asset management services. In addition, it transports re-gasified liquefied natural gas from Saint John, New Brunswick to consumers in the northeastern United States through its 145-kilometer pipeline. As of December 31, 2023, the company's electric utilities served approximately 840,000 customers in West Central Florida; 549,000 customers in Nova Scotia; 134,000 customers in the island of Barbados; 19,000 customers in the Grand Bahama Island; and gas utilities and infrastructure served approximately 490,000 customers across Florida and 540,000 customers in New Mexico. The company was incorporated in 1998 and is headquartered in Halifax, Canada.","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Emera Inc.(EMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Emera Inc.(EMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction